BUL Pacer US Cash Cows Growth ETF
Profitability Metrics
Valuation Metrics
Growth & Cash Flow
Price Change
Top 10 Holdings
| Stock Ticker | Weight |
|---|---|
| BKNG | 4.97% |
| NEM | 4.95% |
| UBER | 4.92% |
| CCL | 4.86% |
| HCA | 4.45% |
| EME | 4.32% |
| TPR | 3.76% |
| EXPE | 3.72% |
| FTI | 3.64% |
| UTHR | 3.42% |
ETF Analysis
Fund Overview
Pacer US Cash Cows Growth ETF (BUL) currently reports 51 stock positions (subject to change), placing it in the moderately broad range by holdings breadth. The top line-up is BKNG (4.97%), NEM (4.95%), UBER (4.92%), with BKNG as the largest single weight at 4.97%. Together, the top three holdings account for 14.84%, which suggests the fund is not overly reliant on its largest positions to generate returns. The fund's architecture positions it to benefit from strength in its top holdings while the broader basket provides a degree of insulation against single-name shocks.
Profitability & Capital Efficiency
Looking at how effectively the underlying holdings deploy capital, ROIC is 33.10%, WACC is 9.41%, and the economic spread is 23.68%. On balance, returns on invested capital exceed the cost of funding by a comfortable margin, which over time compounds favorably for long-term holders. Supporting metrics show ROE at 31.81% and ROA at 10.10%, a combination that helps frame whether profitability strength is broad enough to hold through different market conditions. Taken together, the return profile suggests a portfolio with credible compounding capacity if current operating execution persists.
Valuation
On an earnings multiple basis, trailing P/E of 21.12, forward P/E of 16.51, PEG of 1.35. The gap between trailing and forward multiples is not especially wide, suggesting the market is pricing a steadier earnings path rather than a sharp near-term re-rating. At this PEG level, growth-adjusted valuation looks attractive — the market appears to be paying a reasonable price for the earnings growth embedded in estimates. A current ratio reading of 2.02 points to holdings that are managing short-term obligations without apparent stress. Combining multiples and liquidity, the portfolio appears adequately priced for its current earnings trajectory, with balance sheet health providing a degree of downside resilience.
Margins & Cash Generation
Across the three margin layers, gross margin sits at 56.05%, operating margin at 22.85%, and free cash flow margin at 22.34%. Gross margins sit in a healthy range, consistent with businesses that manage input costs effectively. Operating margins are in good shape, consistent with businesses that maintain reasonable earnings conversion after overhead. At this level, free cash flow margins suggest businesses that are building financial strength alongside revenue growth. Read together, these margins describe businesses that have earned their profitability rather than manufactured it through accounting — a meaningful quality signal.
Growth & Forward Outlook
On a forward-looking basis, TTM revenue growth of 12.74% a signal of steady demand without the volatility of high-growth names, while the estimated 12-month price change of 18.39%, where the target distribution indicates incremental upside rather than outsized repricing. Revenue growth and price targets are correlated but not the same — strong operations do not always translate to strong price appreciation, and vice versa. The forward return case rests on whether the businesses can sustain their operating trajectory long enough for analyst price targets to be reached or exceeded. The estimated 12-month price change is a weighted composite of analyst price target estimates adjusted by each holding's ETF weight, sourced from publicly available data, and should not be interpreted as a reliable prediction of future performance.
Conclusion
Strong BuyThe full scorecard here is hard to argue with: capital efficiency is strong, margins are healthy, and growth is being priced constructively.
The views expressed above are derived from quantitative data only and should not be relied upon as financial advice. Investment decisions should be based on your own research and risk tolerance.